Weight loss

Obese man measures his waist
#Diabetes #Obesity #RedHill Biopharma #Weight loss

Studies support potential treatment for obesity-related disorders

Positive results from multiple in vivo studies have shown the impact of sphingosine kinase-2 (SPHK2) inhibition in various models of metabolic disease. RedHill Biopharma announced the positive study results, which show the effect of opaganib on weight gain and glucose tolerance in a high fat diet… Read More

#News

#Alzheimer's #Cardiovascular disease #GLP-1 #Liver disease #Nicotine addiction #Obesity #Weight loss

New DDW Highlights vodcast: 7 August 2024

Every week, DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates in the DDW Highlights podcast. It is now also available in a concise vodcast format.   GLP-1 receptor agonists have dominated… Read More

#News

#Alzheimer's #Cardiovascular disease #GLP-1 #Liver disease #Nicotine addiction #Obesity #Weight loss

New DDW Highlights podcast: 5 August 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. GLP-1 receptor agonists have dominated the headlines this week, with data revealed on… Read More

#News

#Alzheimer's #Cardiovascular disease #GLP-1 #Liver disease #Nicotine addiction #Obesity #Weight loss

This week in drug discovery (29 July – 2 August) 

News round-up for 29 July – 2 August by DDW Senior Digital Content Editor Diana Spencer. GLP-1 receptor agonists have dominated the headlines this week, with data revealed on new potential beneficial effects of treatment with semaglutide and dual receptor agonists like pemvidutide. The top stories:… Read More

#News

Obese man measures his waist
#GlobalData #GLP-1 #Obesity #Phase II trial #Viking Therapeutics #Weight loss

Obesity drug competition expected to intensify by 2030

Viking Therapeutics’ dual GLP-1/GIP receptor agonist VK2735 could become a direct competitor to Eli Lilly’s Mounjaro/Zepbound (tirzepatide), predicts data analytics company GlobalData. In February 2024, Viking Therapeutics published Phase IIa results for its VK2735 candidate, which is being investigated both as a weekly subcutaneous… Read More

#News

Human liver
#Altimmune #GLP-1 #Liver disease #Phase I trial #Weight loss

GLP-1/glucagon receptor agonist shows promise in liver disease

In a 12-week clinical trial, weekly doses of Altimmune’s pemvidutide resulted in up to 68.5% relative reduction in liver fat content (LFC), with up to 55.6% of subjects achieving LFC normalisation after 12 weeks of treatment. The results of the trial, investigating the GLP-1/glucagon dual receptor… Read More

#Editor's Choice #News

Heart monitor
#Cardiovascular disease #Heart attack #MHRA #Novo Nordisk #Obesity #Weight loss

MHRA approves semaglutide to reduce risk of cardiovascular events

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new indication for semaglutide (Wegovy) to reduce the risk of overweight and obese adults suffering from heart attacks or stroke. The GLP-1 receptor agonist is already approved for use in the treatment of obesity and for weight management,… Read More

#News #Regulatory

Jigsaw puzzle of the brain
#Alzheimer's #Dementia #Diabetes #GLP-1 #Novo Nordisk #Phase II trial #Weight loss

GLP-1 receptor agonist slows Alzheimer’s cognitive decline

In new revelations about glucagon-like peptide-1 (GLP-1) drugs like Ozempic, a study has demonstrated the therapies could protect against dementia. In a Phase IIb trial, Novo Nordisk’s GLP-1 receptor agonist liraglutide appears to reduce shrinking in the parts of the brain that control memory, learning, language… Read More

#News #Trending News

Smoking cessation
#Addiction #Case Western Reserve University School of Medicine #Diabetes #GLP-1 #Nicotine addiction #Smoking cessation #Weight loss

Semaglutide (Ozempic) found to treat smoking addiction

New research has linked semaglutide (the active ingredient in Wegovy and Ozempic) with improved smoking cessation. Rong Xu and colleagues at the Center for Artificial Intelligence in Drug Discovery, Case Western Reserve University School of Medicine, US, have reported a reduced desire to smoke in patients… Read More

#News #Trending News

Man wearing a cap mask while sleeping
#American Diabetes Association #Diabetes #Eli Lilly #GLP-1 #Phase III trial #Sleep apnoea #Weight loss

Weight loss drug reduces sleep apnoea severity by 62%

Tirzepatide demonstrated a mean reduction of up to 62.8% on the apnoea-hypopnea index (AHI) compared to placebo in the SURMOUNT-OSA Phase III clinical trials. The drug was tested for the treatment of moderate-to-severe obstructive sleep apnoea (OSA) in adults with obesity, with and without positive airway… Read More

#News #Trending News

#American Diabetes Association #Diabetes #Events #GLP-1 #Obesity #Weight loss

New evidence on GLP-1 receptor agonists at ADA 2024

Further insights on glucagon-like peptide-1 (GLP-1) receptor agonists were presented at the American Diabetes Association (ADA) 84th Scientific Sessions in Orlando, Florida, 21-24 June. Obesity affects 41.9% of adults and 19.7% of children and adolescents in the US, and 90% of people with diabetes also live… Read More

#News #Trending News

#Cardiovascular disease #Diabetes #GLP-1 #UT Southwestern #Weight loss

Data confirms that semaglutide lowers blood pressure

US scientists have released new data supporting initial findings that diabetes and weight loss drug semaglutide (Wegovy/Ozempic) lowers cardiovascular risk regardless of blood sugar. A weekly dose of semaglutide 2.4mg significantly reduced the risk of major adverse cardiovascular events (MACEs) in people with overweight… Read More

#News #Trending News

Scotland
#Lymphoma #Marketing approval authorisation #NHS Scotland #Scottish Medicines Consortium (SMC) #Ulcerative colitis (UC) #Weight loss

Scottish Medicines Consortium advises on six new drugs

The Scottish Medicines Consortium (SMC), which advises on newly licensed medicines for use by NHS Scotland, has published advice on six medicines. 1. Tirzepatide (Mounjaro) was accepted for weight management in adults and is to be used alongside diet and exercise to help people lose weight. It was also given… Read More

#News #Regulatory

Ozempic Insulin injection pen
#ASCO #Case Western Reserve University #Oncology #Weight loss

Ozempic reduces risk of 13 types of cancer

Patients taking semaglutide (the active ingredient in Wegovy and Ozempic) were 19% less likely to develop 13 obesity-related cancers, according to new data presented at ASCO 2024. The research, led by the Case Western Reserve University in Ohio and reported in The Guardian, also found… Read More

#Cancer Research #News #Trending News

#Microbiome #Neurodegenerative disorders #Oncology #Plant-based #Sepsis #Weight loss

New DDW Highlights podcast: 4 June 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The selected news highlights this week report breakthrough findings from early phase research and… Read More

#News

#Microbiome #Neurodegenerative disorders #Oncology #Plant-based #Sepsis #Weight loss

This week in drug discovery (27-31 May) 

News round-up for 27-31 May by DDW Senior Digital Content Editor Diana Spencer. The selected news highlights this week report breakthrough findings from early phase research and development, mainly preclinical studies and Phase I clinical trials, including a drug that can prevent sepsis deaths, a microbiome based immuno-oncology… Read More

#News